Quantitative structure-activity relationship studies of cyclooxygenase inhibitors: a comprehensive analysis
Authors:
- 1 April 2005
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 64 (4) , 220-231
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- QSAR analyses of conformationally restricted 1,5-diaryl pyrazoles as selective COX-2 inhibitors: application of connection table representation of ligandsBioorganic & Medicinal Chemistry Letters, 2005
- Design and synthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the cyclooxygenase-2 (COX-2) isozymeBioorganic & Medicinal Chemistry Letters, 2005
- QSAR studies on structurally similar 2-(4-methanesulfonylphenyl)pyran-4-ones as selective COX-2 inhibitors: a Hansch approachBioorganic & Medicinal Chemistry Letters, 2005
- Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitorsBioorganic & Medicinal Chemistry Letters, 2004
- QSAR Analysis of 2,3-Diaryl Benzopyrans/Pyrans as Selective COX-2 Inhibitors Based on Semiempirical AM1 CalculationsQSAR & Combinatorial Science, 2004
- QSAR Analysis of Some Fused Pyrazoles as Selective Cyclooxygenase‐2 Inhibitors: A Hansch ApproachArchiv der Pharmazie, 2004
- The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitorBioorganic & Medicinal Chemistry Letters, 1999
- COX-2 inhibitorsThe Lancet, 1999
- The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1Nature, 1994
- The physicochemical approach to drug design and discovery (QSAR)Drug Development Research, 1981